MDACC Study No:2010-0049 ( NCT No: NCT00936858)
Title:A phase II trial using RAD001 for patients with radioiodine refractory thyroid cancer
Principal Investigator:Naifa L. Busaidy
Treatment Agent:RAD001
Study Status:Closed
Study Description:The goal of this clinical research study is learn if RAD001 can help to control
locally-advanced or metastatic thyroid cancer. The safety of this drug will
also be studied.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:RAD001
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:0 days, unless pt gets sick and needs hospitalization for other reasons.
Supported By:Novartis
Return Visit:A treatment cycle consists of 28 days.
Home Care:RAD001 should be taken by the patient in a fasting state or with no more than a
light fat-free meal. A dose of RAD001 is considered missed if the patient did
not take RAD001 within 6 hours of the scheduled time.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naifa L. Busaidy
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2841
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults